Placebo group (n = 20) | Dexmedetomidine group (n = 20) | Ketamine group (n = 20) | P-value | |
---|---|---|---|---|
Incidence of delirium | 15 (75%) | 1 (5%) | 2 (10%) | < 0.001 |
Incidence of cognitive dysfunction | 7 (35%) | 0 (0%) | 2 (10%) | = 0.006 |
Time to 1st postoperative request for analgesia (hours) | ||||
2.30 ± 0.9 | 2.50 ± 0.9 | 4.10 ± 1.1 | < 0.001 | |
P-value | I vs. II = 0.522 | II vs. III < 0.001 | I vs. III < 0.001 | |
The total 24-hour nalbuphine consumption (mg) | ||||
9.25 ± 1.7 | 8.40 ± 1.6 | 6.30 ± 1.4 | = 0.006 | |
P-value | I vs. II = 0.356 | II vs. III = 0.025 | I vs. III = 0.002 | |
Length of hospital stay (days) | ||||
4.55 ± 0.6 | 5.95 ± 0.5 | 6.15 ± 0.3 | = 0.032 | |
P-value | I vs. II = 0.034 | II vs. III = 0.757 | I vs. III = 0.016 |